Paratek Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
June 27, 2016 12:02 ET
|
Paratek Pharmaceuticals
BOSTON, June 27, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock
June 22, 2016 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, June 22, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Announces Proposed Public Offering of Common Stock
June 20, 2016 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, June 20, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 1b Urinary Tract Infection Study
June 20, 2016 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, June 20, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing phase 1b clinical study evaluating omadacycline in the treatment...
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated
June 16, 2016 16:05 ET
|
Paratek Pharmaceuticals
Company to host a webcast and conference call for investors at 4:30 pm EDT to review top-line results BOSTON, June 16, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK)...
Paratek to Present Omadacycline Microbiologic, Pharmacokinetic and Clinical Data at ASM Microbe 2016
June 13, 2016 16:01 ET
|
Paratek Pharmaceuticals
- Biofilm, post-antibiotic effects, microbiologic surveillance and omadacycline in vitro activity against select pathogens to be presented - Clinical PK and Modelling Strategies for omadacycline to...
Paratek Pharmaceuticals, Inc. Announces Participation in JMP Securities Life Sciences Conference
June 01, 2016 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, June 01, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President and Chief Medical Officer, Evan Loh, MD, will participate in the JMP...
Paratek Receives FDA Affirmation for Design of Proposed Omadacycline Oral-Only Skin Infection Phase 3 Study: Opportunity to Accelerate Access to Broader Oral-Only Markets
May 10, 2016 16:01 ET
|
Paratek Pharmaceuticals
FDA Affirms Chosen Comparator, Primary Endpoint for Phase 3 StudyStudy, if Conducted, Would Initiate Following the Reporting of Top-Line Data from IV-to-Oral ABSSSI Phase 3 StudyPotential to...
Paratek Pharmaceuticals, Inc. Reports First Quarter 2016 Financial and Operating Results
May 02, 2016 16:49 ET
|
Paratek Pharmaceuticals
Completed enrollment in Phase 3 ABSSSI studyFaster-than-projected enrollment in Phase 3 CABP studyInitiated dosing in Phase 1b UTI studyConference call scheduled for 8:30 a.m. EDT on May 3, 2016 ...
Paratek Initiates Phase 1b Study of Omadacycline in Urinary Tract Infection
May 02, 2016 16:46 ET
|
Paratek Pharmaceuticals
BOSTON, May 02, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today the dosing of the first patient in its Phase 1b study of omadacycline in patients with Urinary...